+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of iptacopan compared to placebo and standard care in patients with native Complement 3 Glomerulopathy C3G. This Phase 3 pivotal trial aims to assess how iptacopan affects proteinuria levels, kidney function, and kidney tissue changes in both adult and adolescent participants. The study also examines improvements in serum C3 levels as a marker of treatment impact. Participants will be randomly assigned to receive either iptacopan 200 mg twice daily or a matching placebo. Treatment dosing differs slightly for adults and adolescents but follows a twice-daily schedule. The study includes a double-blind treatment period of 12 months, during which kidney biopsies will be performed in adults to evaluate tissue improvements. Vaccinations against certain bacteria are required prior to starting treatment. During the trial, participants will provide urine samples to measure protein levels and have kidney function assessed through estimated glomerular filtration rate eGFR. Safety evaluations include monitoring vital signs, ECGs, and laboratory tests. Fatigue levels will be assessed using a standardized questionnaire. Researchers will follow participants over 6 and 12 months to observe treatment effects and safety, with ongoing assessments during both double-blind and open-label phases.

Age: 12Years - 60YearsAll GendersPhase 3
87 locations